4D Molecular Therapeutics (FDMT) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to -$1.01.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) fell 2784.81% to -$1.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.75, marking a year-over-year decrease of 3157.89%. This contributed to the annual value of -$2.98 for FY2024, which is 1558.7% down from last year.
- As of Q3 2025, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.01, which was down 2784.81% from -$0.98 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.24 during Q3 2023, and registered a low of -$1.01 during Q3 2025.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.77, with a median of -$0.82 in 2021.
- Per our database at Business Quant, 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) surged by 6962.03% in 2023 and then plummeted by 22916.67% in 2024.
- 4D Molecular Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.85 in 2021, then increased by 1.18% to -$0.84 in 2022, then increased by 8.33% to -$0.77 in 2023, then fell by 19.58% to -$0.92 in 2024, then fell by 9.69% to -$1.01 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$1.01 for Q3 2025, versus -$0.98 for Q2 2025 and -$0.86 for Q1 2025.